Biohaven Therapeutics Ltd.

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

6 drugs in development

Phase 31

Phase 22

Phase 12

Preclinical2

By Therapeutic Area

top 5

Neurology

229%

Oncology

229%

Rare Disease

114%

Metabolic & Endocrine

114%

Nephrology

114%

R&D Momentum

49/100

Pipeline Velocity

19/100

Trial Completion Rate

71/100

Pipeline Concentration

22/100

Pipeline Freshness

85/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Rare Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 30, 2026

Completed

Real-World Data Study Assessing the Efficacy of Troriluzole-Treated Subjects With Spinocerebellar Ataxia (SCA) Compared to a Matched External SCA Control Using Natural History Cohort Data

Oct 30, 2026

Active, not recruiting

A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations

Oct 23, 2026

Recruiting

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Earlier

Oct 20, 2026TrialA Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease

Oct 15, 2026TrialA Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder

Oct 15, 2026TrialA Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Major Depressive Disorder (MDD)

Oct 1, 2026TrialA Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Sep 29, 2026TrialA Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

3 more events

Aug 14, 2026TrialA Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Aug 1, 2026TrialAn Open-Label Biomarker Study of BHV-1300 in Graves' Disease

Jul 10, 2026TrialA Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BHV-8000Preclinical

Oncology

Advanced Solid Tumors

BHV-1510Preclinical

Solid Tumor

BHV-1530Phase 1

Rare Disease

Spinal Muscular Atrophy

taldefgrobep alfaPhase 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)